Presentation is loading. Please wait.

Presentation is loading. Please wait.

Comparison of Outcomes with Two Calcineurin Inhibitor-Based Graft-Versus-Host- Disease Prophylactic Regimens after Reduced Intensity Conditioning Allogeneic.

Published byKory Payne Modified over 5 years ago

Similar presentations

Presentation on theme: "Comparison of Outcomes with Two Calcineurin Inhibitor-Based Graft-Versus-Host- Disease Prophylactic Regimens after Reduced Intensity Conditioning Allogeneic."— Presentation transcript:

1 Comparison of Outcomes with Two Calcineurin Inhibitor-Based Graft-Versus-Host- Disease Prophylactic Regimens after Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies  Rashmi Khanal, MD, Valeriy Sedov, MD, Ridhi Gupta, MD, Mark Thomas Burbridge, DO, Colleen Butcher, BSN, RN, OCN, Kylie Capdevila, NP, Kathy Hogan Edwards, PharmD, Kristy Martin, SRA, Amanda Littleton, RN, BSN, OCN, Cindy Kramer, RN, BSN, OCN, Molly Schneider, BSN, RN, APHON, Juan Carlos Varela, MD, PhD, Elizabeth J. Williams, CQIA, Robert Stuart, MD, Saurabh Chhabra, MD, Carolyn Ann Gentles, MSN, FNP  Biology of Blood and Marrow Transplantation  Volume 22, Issue 3, Pages S330-S331 (March 2016) DOI: /j.bbmt Copyright © Terms and Conditions

2 Biology of Blood and Marrow Transplantation 2016 22, S330-S331DOI: (10
Biology of Blood and Marrow Transplantation  , S330-S331DOI: ( /j.bbmt ) Copyright © Terms and Conditions

Download ppt "Comparison of Outcomes with Two Calcineurin Inhibitor-Based Graft-Versus-Host- Disease Prophylactic Regimens after Reduced Intensity Conditioning Allogeneic."

Similar presentations

Comparison of Outcomes with Two Calcineurin Inhibitor-Based Graft-Versus-Host- Disease Prophylactic Regimens after Reduced Intensity Conditioning Allogeneic.

Comparison of Outcomes with Two Calcineurin Inhibitor-Based Graft-Versus-Host- Disease Prophylactic Regimens after Reduced Intensity Conditioning Allogeneic.
Topical Ruxolitinib Protects LGR5+ Stem Cells in the Hair Follicle and Ameliorates Skin Graft-Versus-Host Disease  Shuichiro Takahashi, MD, Daigo Hashimoto,

Topical Ruxolitinib Protects LGR5+ Stem Cells in the Hair Follicle and Ameliorates Skin Graft-Versus-Host Disease  Shuichiro Takahashi, MD, Daigo Hashimoto,
Efficacy and Safety of Ciprofloxacin for Prophylaxis of Polyomavirus BK Virus– Associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplantation.

Efficacy and Safety of Ciprofloxacin for Prophylaxis of Polyomavirus BK Virus– Associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplantation.
Stephanie J. Lee, Loretta A. Williams 

Stephanie J. Lee, Loretta A. Williams 
Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation
Prognostic Importance of Functional Capacity for Pre-Transplant Risk Assessment Among Patients Undergoing Allogeneic Hematopoietic Cell Transplantation 

Prognostic Importance of Functional Capacity for Pre-Transplant Risk Assessment Among Patients Undergoing Allogeneic Hematopoietic Cell Transplantation 
Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant  Maria Gil-Cupello, BA, Gunjan.

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant  Maria Gil-Cupello, BA, Gunjan.
Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 
Improvement in Hematopoiesis with Treatment of Iron Overload Following Allogeneic Transplants  Akash Mukherjee, MD, Dhaval Shah, MD, Gloria Obi, PhD,

Improvement in Hematopoiesis with Treatment of Iron Overload Following Allogeneic Transplants  Akash Mukherjee, MD, Dhaval Shah, MD, Gloria Obi, PhD,
Liver Transplantation for Hepatic Graft-Versus-Host-Disease: A United Network for Organ Sharing (UNOS) Database Study  Shahrukh Hashmi, MD MPH, Timucin.

Liver Transplantation for Hepatic Graft-Versus-Host-Disease: A United Network for Organ Sharing (UNOS) Database Study  Shahrukh Hashmi, MD MPH, Timucin.
Using A3 Methodology to Identify the Root Cause of a Chemotherapy Error in a Hematopoietic Stem Cell Transplant Patient  Kathlene DeGregory, PharmD, BCOP,

Using A3 Methodology to Identify the Root Cause of a Chemotherapy Error in a Hematopoietic Stem Cell Transplant Patient  Kathlene DeGregory, PharmD, BCOP,
Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.
Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia  Katerina Ancevski,

Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia  Katerina Ancevski,
Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease  Fevzi F. Yalniz, Mehrdad Hefazi, Kristen.

Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease  Fevzi F. Yalniz, Mehrdad Hefazi, Kristen.
Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,
Systematic Anti-Mold Prophylaxis Results in Very Low Incidence of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation 

Systematic Anti-Mold Prophylaxis Results in Very Low Incidence of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation 
Allogeneic Hematopoietic Cell Transplantation (HCT) Results in Better Time to Next Therapy (TTNT) Than Chemotherapy (CT) in Chronic Lymphocytic Leukemia.

Allogeneic Hematopoietic Cell Transplantation (HCT) Results in Better Time to Next Therapy (TTNT) Than Chemotherapy (CT) in Chronic Lymphocytic Leukemia.
Higher Apheresis Blood Volumes Are Associated with a Reduction in Relapse Risk and Improved Survival in Patients Undergoing Reduced Intensity Allogeneic.

Higher Apheresis Blood Volumes Are Associated with a Reduction in Relapse Risk and Improved Survival in Patients Undergoing Reduced Intensity Allogeneic.
Access to Hematopoietic Cell Transplantation in the United States

Access to Hematopoietic Cell Transplantation in the United States
Outcomes after Matched Unrelated Donor and Haploidentical Related Donor Allogeneic Transplantation for Hematological Malignancies: Single Center Experience 

Outcomes after Matched Unrelated Donor and Haploidentical Related Donor Allogeneic Transplantation for Hematological Malignancies: Single Center Experience 

Similar presentations

Ads by Google